The problem of inhalation of Aspergillus spores outside rooms with high-efficiency particulate air (HEPA) filtration has not been resolved as yet. Well-fitting masks are used in industrial and health care settings to protect from inhaling particles of 0.3-0.5 lm size. To investigate the efficacy and tolerability of well-fitting masks in high-risk patients, we conducted a prospective, randomised, multicentre study comparing standard hospital hygiene procedures with or without wearing masks in adults undergoing chemotherapy for acute leukaemia or allogeneic haematopoietic stemcell transplantation (aHSCT). Forty-one patients were randomly assigned to wearing masks and 39 to the control group. In all, 76% of patients were treated in laminar airflow or HEPA-filtered rooms, 84% received oral polyenes, and three aHSCT recipients were given fluconazole. Duration of neutropenia was similar in both treatment groups. Invasive fungal infections were diagnosed in eight patients in either study arm. One patient in each arm died from proven invasive aspergillosis. There was no difference in the use of systemic antifungals. Of patients in the mask group, 65% described the comfort as acceptable, 26% as unpleasant, and 9% as intolerable. This first randomised study on the use of well-fitting masks failed to show a reduction of invasive fungal infections.
introduction
Filamentous fungal infections, particularly invasive aspergillosis (IA), have become predominant causes of morbidity and mortality in patients with profound and prolonged neutropenia [1] [2] [3] . Patients with acute myeloid leukaemia undergoing intensive chemotherapy have an 7% to 11% risk of developing proven or probable IA [4, 5] , while under conditions of high burden of airborne Aspergillus spores such as reconstruction activities, this incidence can dramatically increase to up to 40% [6] . Infection control recommendations include patient accommodation in single or two bed rooms with high-efficiency particulate air (HEPA) filtration, which have been demonstrated to reduce the incidence of IA in acute leukaemia and other high-risk patients [6] [7] [8] . However, air filtration equipments are limited to patient rooms and/or wards. The problem of inhalation of Aspergillus spores outside these rooms, mainly on transport for diagnostic procedures or in an outpatient setting, has not been resolved as yet.
Well-fitting masks fulfilling criteria of the N95 standard in the United States or the FFP2 class in Germany are used in industrial and health care settings to protect workers from inhaling health-threatening particles by filtrating at least 95% of particles of 0.3-0.5 lm size [9, 10] . In contrast, surgical masks routinely used by high-risk patients in many institutions have been shown not to prevent the penetration of these particles sufficiently [10] , and their benefit for these patients has never been shown clinically. N95 masks have been used during a time period of hospital construction to protect neutropenic patients on transport from hospital rooms from inhalation of Aspergillus spores [11] . In comparison with a historical control group, they found a reduction of nosocomial aspergillosis below the rate before hospital construction and concluded that wearing well-fitting masks provides effective protection. The original article 
patients and methods
Hospitalised patients of at least 18 years of age who were undergoing intensive myelosuppressive chemotherapy for acute leukaemia or allogeneic haematopoietic stem-cell transplantation (aHSCT) and who had given their written consent were eligible for the study. Exclusion criteria were the presence of a possible, probable, or proven IA [13] in the patient's medical history, unwillingness to cease cigarette smoking, participation in another study on antifungal prophylaxis, previous inclusion in the present study, and any factors with a potential negative impact on patient compliance to adhere to the protocol, such as mental impairment, psychiatric disorder, or insufficient knowledge of the German language. Institutions in which wearing of any type of masks by the patients as part of their routine programmme were not included.
After checking for exclusion and inclusion criteria, randomisation was carried out via telephone according to a previously produced randomisation list for each participating centre. Patients were allocated to receive the locally established routine prophylaxis such as protective isolation, HEPA filtration, oral nonabsorbable polyenes, low-microbial diet, or oral fluconazole (restricted to allogeneic haematopoietic stem-cell transplant recipients) plus nothing or plus a well-fitting FFP2 mask (3M Lübeck, Germany) to be used without interruption whenever the room was left. Antibacterial prophylaxis was not regulated by the protocol.
In case of fever, patients were managed according to the published clinical guidelines of the AGIHO [14, 15] . In short form, for initial diagnostics at the onset of fever, physical examination, chest radiograph, two pairs of blood cultures, a defined panel of clinical chemistry parameters, and additional microbiological test if indicated were prescribed. For fever of unknown origin, treatment with an antipseudomonal broad-spectrum beta-lactam antibiotic with or without an aminoglycoside was started within 2 h. For patients not responding after a minimum of 72 h of antibiotic treatment, a high-resolution or multislice thoracic computed tomography was carried out. If patients had pulmonary infiltrates, fibreoptic bronchoscopy with bronchoalveolar lavage was recommended. The use of Aspergillus galactomannan doublesandwich enzyme-linked immunosorbent assay or PCR screening from serial blood samples was recommended, but not prescribed by the protocol.
Patients assigned to wear the FFP2 masks completed a simple daily report on their constant adherence to the protocol, the tolerance or any discomfort related to the wearing of the masks, and the frequency of leaving their rooms. Physicians responsible for the individual study patients documented the compliance of patients to the protocol by one of the four predefined criteria (very good, good, sufficient, and noncompliant) based upon their assessment and interviews during their visits. The masks were changed on a daily basis or whenever required by the patient. The duration of the study in an individual patient was terminated by one of the following criteria: withdrawal of consent, start of systemic antifungal treatment active against aspergillosis, end of hospitalisation, or start of next chemotherapy cycle.
Primary end point of the study was the occurrence of possible, probable, or proven aspergillosis according to the consensus criteria of the European Organisation for Research and Treatment of Cancer and the Mycoses Study Group [13] . Secondary end points were tolerability, patient compliance with wearing the masks and other procedures related to infection prevention, mortality and the administration of systemic antifungal agents for empirical or targeted treatment of invasive mycoses, and diagnosis of fungal infection within 2 weeks after study.
For sample size calculation, an overall incidence of possible, probable, or proven aspergillosis of 25% in the control arm was assumed. To demonstrate a reduction of this incidence by >50% with an alpha error of 0.05, a beta error of 0.20, and a power of 0.80 and hypothesising a 90% rate of assessable patients, a total of 192 patients were to be recruited [16] .
The study protocol was approved by the Ethics Committee of Charité University Hospital of Berlin, Germany, under file no. 166/2003.
Masks were provided by 3M Germany for free. The manufacturer had no further role in this study.
results
From February 2004 to October 2005, a total of 80 patients were entered from eight participating institutions. The recruitment was stopped at this time because of the first presentation of two prospective, randomised studies demonstrating a significant benefit of systemic antifungal prophylaxis with posaconazole with respect to the incidence of filamentous fungal infections, and in one of them, also with respect to survival among patients with acute leukaemia or myelodysplastic syndrome undergoing intensive chemotherapy or patients with moderate-to-severe graft-versus-host disease after aHSCT [4, 17] .
Patient characteristics are depicted in Table 1 . Forty-five patients were males and 35 patients females. Mean age was 49 years, with 19 patients being <41, 38 patients between 41 and 60, and 23 patients >60 years of age. Their underlying diseases were acute myeloid leukaemia (n = 60), acute lymphoblastic leukaemia (n = 14), and other acute leukaemia (n = 1), while five patients after allogeneic stem-cell transplantation were included. Fifty-four patients were undergoing first remission induction chemotherapy, 20 were in complete remission and underwent consolidation chemotherapy or transplantation, four were given chemotherapy for relapse, and the status was not specified in two patients.
By randomisation, 41 patients were assigned to wearing masks and 39 patients to the control group.
Sixty one of 80 patients (76%) were treated in laminar airflow and/or HEPA-filtered rooms. Sixty seven (84%) received topical nonabsorbable suspensions of amphotericin B or nystatin, and three patients after aHSCT (3.75% of total) were given oral fluconazole.
Median duration of neutropenia was 21.2 (4-85) days. Neutropenia lasted 1-10 days in nine patients, 11-20 days in 31 patients, 21-30 days in 23 patients, 31-40 days in three patients, 41-50 days in six patients, and >50 days in three patients. Duration of neutropenia was not precisely noted in five patients. The duration of neutropenia was evenly distributed between the two patient groups.
Overall study results with respect to fungal infections and fatalities are shown in Figure 1 . Invasive fungal infections were diagnosed in 16 patients (eight in either study arm), with no difference between study arms (Table 2) . Of these fungal infections, seven were possible aspergilloses, three probable aspergilloses, and two proven aspergilloses (one in each arm). Invasive fungal infections other than aspergillosis occurred in three patients assigned to wearing masks and two patients in the control arm. One of the latter two patients had invasive candidosis plus IA. One patient in each arm died of proven IA; another two patients (one in each arm) died of other causes. There was no significant difference in the use of systemic antifungals between the two groups. Overall, voriconazole was given to 18 patients, conventional or lipid-based amphotericin B to 15 patients, itraconazole to six patients, and fluconazole or caspofungin to four patients. Of patients in the mask group, 65% described the comfort as acceptable, 26% as unpleasant, and 9% as intolerable. Patients wore the masks for a median of 20 days. Of a total of 724 days, the comfort was noted by the patients to be acceptable in 79%, as unpleasant in 19%, and as intolerable in 2% of days.
Patients left their rooms for a median of seven times, with a broad range between 0 and 40 times.
Of 78 patients assessable for their compliance with prophylactic measures, compliance to prophylaxis procedures was noted to be good or very good in 72 (92.3%), with no significant difference between the two groups. In two patients, compliance was not assessable.
Among the eight patients in the mask group, in whom invasive fungal infection was diagnosed, compliance was excellent in three and good in four, while in one patient, the compliance was not specified. This patient had clinically and autopsy-proven fatal IA.
There was no correlation between poor compliance, documentation of intolerability, and the occurrence of invasive fungal infections. In none of the patients with invasive fungal infection, insufficient compliance with regards to wearing their masks was noted.
In 61 patients, the study was terminated due to discharge from hospital after completion of chemotherapy (n = 41) or start of next chemotherapy cycle (n = 20), in three because of a documented fungal infection (two in the mask group and one in the control group) and in three patients because of death (two in the mask group and one in the control group). In the 2-week follow-up period, four possible invasive aspergilloses were diagnosed in the mask group and one probable aspergillosis in the control group.
Hospital building construction during this study was reported from one of the participating centres. This centre had recruited 26 patients to the study. Of these, one possible aspergillosis was documented in a patient in the control group and another possible aspergillosis during follow-up period in a patient of the mask group.
discussion
It is well accepted that IA in severely immunosuppressed patients may be acquired nosocomially via inhalation of dust contaminated with fungal spores [18, 19] , particularly as a consequence of hospital construction work [6, 20, 21] and that there is a correlation between the load of fungal spores in environmental air and the incidence of IA [22] . A decrease of infection rates has been achieved by a reduction of patient exposure to contaminated air [6, 23] , particularly during hospital construction activities [11, 21, 24] . Isolation wards equipped with HEPA filters have been repeatedly shown to be beneficial in terms of reduced incidence of aspergillosis [6, 7, 24, 25] . However, those wards are not principally available for each patient with acute myeloid leukaemia, and patients more or less frequently leave their wards in order to undergo medical procedures such as radiological diagnostics or endoscopies. The wearing of filtering masks is a widely used clinical routine in these patients. Disposable surgical masks, although most frequently employed, are not suitable for effectively filtering small particles [26] , whereas masks according to the N95 standard in the United States or the FFP2 class in Europe have been proven to effectively prevent inhalation of these particles, including fungal spores [9, 10] , provided they are well fitting [26] .
In contrast to current recommendations to incorporate wellfitting masks into infection control programmes aiming at the reduction of nosocomially acquired pulmonary aspergillosis [11, 12, 27, 28] , our study results do not support this recommendation. Although the trial had to be discontinued before the scheduled number of patients were recruited, and therefore has been statistically underpowered, it appears unlikely that a larger study population would have shown significant differences because among the 41 patients assigned to wearing well-fitting masks, not even a slight trend to less invasive aspergilloses could be observed. Statistically, a difference of at least 19% would have to be present to be detected with a power of 80%, i.e. a reduction from 20% to 0% between the two study groups, so that a prolongation of the study period presumably would not have been useful.
The consequence from our observation may be to agree to approaches proposed by investigators from Calgary [29] and from Stockholm [30] , who prefer less rigorous isolation and infection control procedures [29] or even home care [30] of patients undergoing aHSCT. Since for patients undergoing intensive myelosuppressive chemotherapy for remission induction in acute myeloid leukaemia, such an approach appears risky, data obtained by Berthelot et al. [27] , favouring well-fitting masks as part of a complex multidisciplinary approach involving engineers, infection control practitioners, mycologists, and clinicians in order to reduce IA rates among patients hospitalised in haematology wards appear to be more feasible. In our study, all standard hygiene procedures established for preventing nosocomial fungal infections were followed, and masks apparently did not add any benefit to them. Of note, in one centre where hospital construction was ongoing during the study, no benefit of wearing a well-fitting mask in addition to the other hygiene procedures was observed.
Possible explanations for the failure of the use of masks in our study would be that patients enter the hospital already colonised by Aspergillus spp. acquired from their individual environment and develop IA originating from their colonising fungal strain. However, data on molecular epidemiology of IA do not support this assumption and confirm the preferably nosocomial origin of IA [31] . Single cases of aspergillosis occurred in the follow-up period after the study. Prolonged use of the masks might have prevented these. At the same time, however, it must be taken into account that in patients undergoing aHSCT, the majority of cases of IA occur late after transplant, i.e. after discharge from hospital [32, 33] . Therefore, particularly taking the most recently published data on the efficacy of antifungal chemoprophylaxis with posaconazole into account [4, 17] , it appears more likely that high-risk patients undergoing intensive myelosuppressive chemotherapy for acute myeloid leukaemia or those with graft-versus-host disease after aHSCT will benefit from effective antifungal chemoprophylaxis rather than from strict measures to prevent inhalation of Aspergillus spores by wearing masks. However, with respect to reports on increasing number of multi-azole-resistant Aspergillus spp. [34] , alternatives to systemic antifungal chemoprophylaxis, e.g. inhalation of liposomal amphotericin B [35, 36] , should further be explored.
acknowledgements
The authors thank 3M Germany for providing FFP2 masks free of charge, Gerald Splettstößer, Koordinierungszentrum für Klinische Studien, Charité Berlin, for support in the statistical design of the study, Simone Wendt for excellent data management, and our patients for their participation in the study.
references
